A pilot study evaluating interleukin-2-activated hematopoietic stem cell transplantation for hematologic malignancies

Journal of Hematotherapy and Stem Cell Research

Volumn 6, Issue 5, 1997, Pages 457-464

  Meehan, Kenneth R ^a   Badros, Ashraf ^a   Frankel, Stanley R ^a   Cahill, Richard ^a   Areman, Ellen ^a   Jenson, Michelle ^a   Sacher, Ronald ^a   Mazumder, Amitabha ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; FEMALE; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HEMATOPOIETIC STEM CELL; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; PILOT PROJECTS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0030832807     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.1.1997.6.457     Document Type: Article

References (27)

1. Maraninchi, D., Blaise, D., Viens, P., et al. High-dose recombinant interleukin-2 and acute myeloid leukemia in relapse. Blood 78:2182, 1991.
2. Gisselbrecht, C., Maraninchi, D., Milpied, N., et al. Interleukin-2 treatment in lymphoma: A phase II multicenter study. Blood 83:2081, 1994.
3. Gottlieb, D.J., Brenner, M.K., Heslop, H.E., et al. A phase I clinical trial of recombinant interleukin-2 following high dose chemo-radiation at minimal residual disease. Br. J. Cancer 60:610, 1989.
4. Foa, R., Melon, G., Tosti, S., et al. Treatment of acute myeloid leukemia patients with recombinant interleukin 2. A pilot study. Br. J. Haematol. 77:491, 1991.
5. Smith, K.A. Interleukin-2: Inception, impact and implications. Science 240:1169, 1988.
6. Rayner, A.A., Grimm, E.A., Lotze, M.T., et al. Lymphokine activated killer (LAK) cell phenomenon. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J. Natl. Cancer Inst. 75:67, 1985.
7. Chadwick, B.S. & Miller, R.G. Heterogeneity of the lymphokine-activated killer cell phenotype. Cell. Immunol. 132:168, 1991.
8. Charak, B.S., Brynes, R.K., Groshen, S., et al. Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 8:2187, 1990.
9. Charak, B.S., Brynes, R.K., Katsuda, S., et al. Induction of graft versus leukemia effect in bone marrow transplantation: Dosage and time schedule dependency of interleukin-2 therapy. Cancer Res. 51:2015, 1991.
10. Charak, B.S., Agah, R., Brynes, R.K., et al. Interleukin-2 and IL-2 activated bone marrow transplantation: Evaluation from a clinical perspective. Bone Marrow Transplant. 9:479, 1992.
11. Charak, B.S., Malloy, B., Agah, R., et al. A novel approach to purging of leukemia by activation of bone marrow with interleukin-2. Bone Marrow Transplant. 6:193, 1990.
12. Meehan, K.R., Verma, U.N., Rajagopal, C., et al. Stem cell transplantation with chemoradiotherapy and interleukin-2. J. Infus. Chemother. 6:28, 1996.
13. Meehan, K.R., Rajagopal, C., Verma, U.N., et al. Biologic and clinical correlates of interleukin-2 administration in peripheral blood stem cell transplantation for breast cancer. Blood 86:389a, 1995.
14. Meehan, K.R., Verma, U.N., Cahill, R., et al. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: Investigation of dose level with clinical and biological correlates. Bone Marrow Transplant. 1997 In press.
15. Verma, U.N., Areman, E., Dickerson, S.A., et al. Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors. Bone Marrow Transplant. 15:199, 1995.
16. Rill, D.R., Santana, V.M., Roberts, W.M., et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorgenic cells. Blood 84:380, 1994.
17. Shpall, E.J. & Jones, R.B. Release of tumor cells from bone marrow. Blood 83:623, 1994.
18. Soifer, R.J., Murray, C., Cochran, K., et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell depleted allogeneic bone marrow transplantation. Blood 79:517, 1992.
19. Biaise, D., Olive, D., Stoppa, A.M., et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 76:1092, 1990.
20. Higuchi, C.M., Thompson, J.A., Petersen, F.B., et al. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 77:2561, 1991.
21. Hamm, M.D., Prentice, H.G., Gottlieb, D.J., et al. Therapy with interleukin-2 after autologous bone marrow transplantation in acute myelogenous leukemia. Bone Marrow Transplant. 11:399, 1993.
22. Klingemann, H.G., Eaves, C.J., Barnett, M.J., et al. Transplantation of patients with high-risk acute myeloid leukemia in first remission with autologous bone marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant. 14:389, 1994.
23. Gaspari, A.A., Lotze, M.T., Rosenberg, S.A., et al. Dermatologic changes associated with IL-2 administration. JAMA 258:1624, 1987.
24. Kennedy, M.J., Vogelsang, G.B., Jones, R.J., et al. Phase I trial of interferon gamma to potentiate cyclosporin-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J. Clin. Oncol. 12:249, 1994.
25. Kennedy, M.J. & Jones, R.J. Autologous graft versus host disease: Immunotherapy of breast cancer after bone marrow transplantation. Breast Cancer Res. Treat. 26 (Suppl.):S31, 1993.
26. Massumoto, C., Benyunes, M.C., Sale, G., et al. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant. 17:351, 1996.
27. Weber, J.S., Yang, J.C., Topalian, S.C., et al. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin lymphoma. J. Clin. Oncol. 10:33, 1992.